Suzanne Leijen

1. Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
   2016/12/20 by Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke +10 · 4 citations
   Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer-related Molecular Pathways #Ovarian cancer diagnosis and treatment #Renal and related cancers